A Study Investigating Peripheral Cryoneurolysis in Adults With Chronic Migraine

Launched by ST. OLAVS HOSPITAL · Aug 12, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment for adults suffering from chronic migraines, which are defined as having 15 or more headache days per month. The treatment being tested is called cryoneurolysis, a freezing technique that aims to reduce headache pain. The study will recruit 12 adults aged 18 and older who have a history of debilitating headaches despite trying various medications. To qualify, participants should have experienced chronic migraines for at least a year and have not found relief from at least three different types of migraine medications.

If you decide to participate, you will keep a diary of your headaches for at least four weeks before receiving the freezing treatment. After the treatment, you will continue to track your headaches, and if your migraines return, you may receive additional treatments for up to two years. This study is a crucial step in determining whether cryoneurolysis could be an effective option for managing chronic migraines, and it aims to gather important information that may lead to further research on this type of treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participant must be 18 years at the time of signing the informed consent
• • 2. Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria 1.3. for chronic migraine at time of inclusion, verified by a neurologist
• • 3. History of 8 debilitating headache days per month for at least 3 consecutive months. Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy at the recommended dose and taken early during the attack; failure of at least two different triptans is required.
• • 4. Chronic migraine at least for a period of 1 year prior to inclusion
• • 5. Debut of episodic migraine before the age of 50, and chronic migraine before the age of 65.
• • 6. The condition is pharmacologically resistant as defined in EHF guidelines as lack of efficacy, lack of tolerability and/or contraindications to at least 3 of the following drug classes
• • 1. Antidepressant (Amitryptyline, Venlafaxine)
• • 2. Antiepileptic (Topiramate or Valproate)
• • 3. Beta-blocker (Atenol, Metropolol, Propanolol, Timolol)
• • 4. Calcium channel blockers (Flunarizine or Cinnarizine)
• • 5. Drugs acting on the CGRP pathway (Monoclonal antibodies and gepants)
• • 6. Angiotensin-converting enzyme inhibitors (Lisinopril) or angiotensin II receptor blocker (Candesartan)
• • 7. OnabotulinumtoxinA
• • 7. Subject has had no change in type, dosage or dose frequency of preventive headache medications \< 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer.
• • 8. Subjects has not been treated with steroids orally or injections \>8 weeks (excluding steroid inhalations or topical treatments) prior to baseline and agrees to refrain from steroids orally or injections during baseline and 8 weeks post-intervention.
• • 9. Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during baseline and 8 weeks after the intervention.
• • 10. Be an appropriate candidate for the study intervention required in this study on the basis of the clinical judgment of the investigator
• • 11. Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Exclusion Criteria:
• • 1. Subject is unable to differentiate migraine from other concomitant headaches.
• • 2. Subject with secondary headache conditions, with the exception of medication overuse headache.
• 3. Subject that, in the opinion of the investigator, has had no or minimal response to more than 6 adequate trials of prophylactic migraine treatment of the following drug classes:
• • 1. Antidepressant (Amitryptyline, Venlafaxine)
• • 2. Antiepileptic (Topiramate or Valproate)
• • 3. Beta-blocker (Atenol, Metropolol, Propanolol, Timolol)
• • 4. Calcium channel blockers (Flunarizine or Cinnarizine)
• • 5. Drugs acting on the CGRP pathway (Monoclonal antibodies and gepants)
• • 6. Angiotensin-converting enzyme inhibitors (Lisinopril) or angiotensin II receptor blocker (Candesartan)
• • 7. OnabotulinumtoxinA
• • 4. Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period.
• • 5. Ongoing abuse of drugs (including narcotics) or alcohol.
• • 6. More than 4 days of opioid use per month (including codeine and tramadol), and any use of barbiturates
• • 7. Other pain conditions, not intended to be treated in this study, that in the opinion of the investigator could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints.
• • 8. High probability of deterioration due to other medical conditions, that in the opinion of the investigator may confound outcome assessment.
• • 9. Other coexisting current medical conditions, including, but not limited to, bleeding diathesis and thrombophilia, that presents excess procedural risk, in the opinion of the investigator.
• • 10. Abnormal pain behavior, inappropriate medication use and/or unresolved psychiatric illness, that in the opinion of the investigator are significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.
• • 11. Anomaly or trauma which renders the planned procedure difficult.
• • 12. Subject currently has an active abscess or a local infection at the site of intervention based on present symptoms.
• • 13. Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving skull or site of intervention that have been active or required treatment in the past 6 months.
• • 14. Patients with any kind of conductive implant with contraindication for nerve stimulation.
• • 15. The subject is not competent to consent